Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.

Abstract: Stable immunogens comprising portions of the inner domain (ID) of the Human Immunodeficiency Virus (HIV-1) gp120 protein are provided. These ID immunogens selectively present the gp120 C1/C2 region in its CD4-bound state within a minimal structure. These ID immunogens can be used to vaccinate subjects against infection with HIV, the causative agent of Acquired Immunodeficiency Syndrome (AIDS). The immunogens can also be used as targets in screening to identify small molecule or peptide inhibitors that block HIV-1 viral entry and attachment steps, and as probes for identifying gp120 C1/C2 region-specific antibodies.

Abstract: This disclosure relates to binding agents with specificity for HIV and to methods for using the same to treat, prevent and/or ameliorate HIV infection and/or AIDS.

Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.

Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.

Abstract: Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-? (TGF?). TGF?-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGF?1, compared to human TGF?2 and human TGF?3, or may selectively bind human TGF?3, compared to human TGF?1 and human TGF?2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGF?2 and by another co-crystal structure of the scFv version of GC1008 bound to TGF?1.

Abstract: An anti-HMGB1 antibody comprising a light chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 4 to 6, and a heavy chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 10 to 12, or an anti-HMGB1 antibody comprising a light chain variable region or the like comprising an amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region comprising an amino acid sequence or the like of SEQ ID NO: 9, and a composition for treating or preventing Alzheimer's disease, comprising the same as an active ingredient.

Abstract: Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.

Abstract: A novel domain of Aggrus involved in the binding to CLEC-2 was searched for, and monoclonal antibodies recognizing the domain were obtained. The newly found PLAG4 domain is important for Aggrus binding to CLEC-2. Monoclonal antibodies recognizing this region were further developed. The present invention can provide novel Aggrus-CLEC-2 binding inhibitors, platelet aggregation inhibitors, cancer metastasis inhibitors, and tumor growth inhibitors using these antibodies.

Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.

Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

Abstract: The invention relates to protein-based T-cell receptor knockdown, and its use in T-cell therapies.

Abstract: The present invention relates to a polypeptide comprising (a) a first set of six complementarity determining regions (CDRs) configured to bind a first antigen; and (b) (ba) a second set of six CDRs configured to bind a second antigen; or (bb) a ligand capable of binding to a second antigen; wherein (i) said first antigen is selected from Hepatitis B virus (HBV) small surface antigen; HBV medium surface antigen; and HBV large surface antigen; and (ii) said second antigen is selected from surface antigens presented by immune effector cells such as natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Also provided are compositions for use in a method of treating or preventing HBV infection and/or a condition caused by said HBV infection, said condition caused by said HBV infection being selected from liver cirrhosis and hepatocellular carcinoma.

Abstract: Anti-CD8 antibodies, radiolabeled anti-CD8 antibodies, fluorescently labeled anti-CD8 antibodies and their use in imaging are provided herein. Included are methods of detecting the presence of CD8 proteins in a subject or sample.

Abstract: The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.

Abstract: Disclosed herein are recognition molecules that bind with a first binding domain to the Fc epsilon receptor (Fc?eR) and with a second binding domain to the Fc gamma receptor IIB (FcyRIIB), as well as uses for such recognition molecules.

Abstract: The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.

Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.

Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.

Abstract: Provided herein are antibodies that specifically bind to GITR. Also described are related polynucleotides capable of encoding the provided GITR-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to enhance an immune response in a subject against cancer.

Abstract: The invention provides anti-OX40 antibodies and methods of using the same.

Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.

Abstract: The present disclosure provides novel anti-PD-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.

Abstract: Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.

Abstract: A monoclonal antibody that binds to an extracellular domain of human receptor-type protein tyrosine phosphatase ? (human PTPRS), or a fragment including an antigen-binding region thereof.

Abstract: A process for producing a water-soluble cellulose derivative of a reduced content of water-insoluble particles comprises the steps of a) reacting cellulose with an alkaline material to produce alkali cellulose, b) reacting the produced alkali cellulose with one or more derivatizing agents to produce a water-soluble cellulose derivative, c) washing the produced cellulose derivative with an aqueous liquid once or several times to provide a moist cellulose derivative having a water content of 25 to 85 percent, based on the total weight of the moist cellulose derivative, d) subjecting the moist cellulose derivative to homogenization to form the moist cellulose derivative to a paste, and e) pressing the paste through a filter of a pore size of up to 200 ?m.

Abstract: In a process for preparing an esterified cellulose ether a cellulose ether is esterified with (i) an aliphatic monocarboxylic acid anhydride or (ii) a dicarboxylic acid anhydride or (iii) a combination of an aliphatic monocarboxylic acid anhydride and a dicarboxylic acid anhydride in the presence of an alkali metal carboxylate and an aliphatic carboxylic acid, wherein the molar ratio [alkali metal carboxylate/anhydroglucose units of cellulose ether] is not more than [1.20/1] and the molar ratio [aliphatic carboxylic acid/anhydroglucose units of cellulose ether] is from [3.55/1] to [9.0/1].

Abstract: A method to convert at least a majority of native cellulose I? to cellulose IIII in pretreated or untreated densified biomass is disclosed. The densified biomass (cellulosic or lignocellulosic) is pretreated with anhydrous liquid ammonia or liquid ammonia comprising a solution of at least 80% ammonia. The pretreating can be performed at a temperature from about 4° C. to about 140° C. and a pressure from about 14.7 to about 200 psi. In one embodiment, the densified cellulosic converting pretreatment process is followed by lignin extraction (LE). The total moisture content of the densified biomass and the solution is 30% or less and a weight ratio of liquid ammonia to the densified biomass is from about 0.3:1 to about 2:1. Various products and systems are also disclosed.

Abstract: The present invention describes tunable methods of treating cellulosic materials with a composition that provides increased hydrophobicity and/or lipophobicity to such materials without sacrificing the biodegradability thereof. The methods as disclosed provide for binding of saccharide fatty acid esters on cellulosic materials, including that the disclosure provides products made by such methods. The materials thus treated display higher hydrophobicity, lipophobicity, barrier function, and mechanical properties, and may be used in any application where such features are desired.

Abstract: Methods of treating, inhibiting and/or preventing instant blood-mediated inflammatory reaction (IBMIR) comprise administering, to a subject, a dextran sulfate characterized by a number average molecular weight (Mn) as measured by nuclear magnetic resonance (NMR) spectroscopy within an interval of 1850 and 3500 Da; an average sulfate number per glucose unit within an interval of 2.5 and 3.0; and an average sulfation of C2 position in the glucose units of said dextran sulfate of at least 90%, or a salt of such a dextran sulfate.

Abstract: Disclosed herein are processes for preparing functionalized polymers, functionalizing compounds useful in the processes and processes for preparing the functionalizing compound. The processes for preparing a functionalized polymer include reaction of a functionalizing compound (prepared from the reaction of an alkoxysilane compound of formula (I) with a polyol of formula (II)) with a reactive conjugated diene monomer-containing polymer, thereby producing a polymer end functionalized with the functionalizing compound. In certain embodiments, the functionalizing compound has a formula according to formula (III), (IV), or (V).

Abstract: A rheology modifier obtainable by polymerizing (i) at least one ethylenically unsaturated carboxylic acid; (ii) at least one nonionic ethylenically unsaturated surfactant monomer, (iii) at least one C1-C2-alkyl methacrylate, and (iv) at least one C2-C4-alkyl acrylate, where the alkyl chain length averaged over the number of alkyl groups of the alkyl acrylate is 2.1 to 4.0. The polymerization is carried out in the presence of at least one hydrocarbon comprising at least one XH-group, wherein X is selected from the group consisting of O, P, N and S. Liquid formulations and particles containing liquid detergents comprising the rheology modifier are also described.

Abstract: A process for preparing aqueous dispersions of polymers containing oxazoline groups, by aqueous emulsion polymerization initiated by free radicals. The polymerization are carried out in two stages. In the first polymerization stage, an ?,?-monoethylenically unsaturated compound having at least one acid group, an monoethylenically unsaturated compound having at least one carboxylic acid amide group, a monoethylenically unsaturated compound having at least one carboxylic acid amide group are copolymerized. In the second polymerization stage, a monoethylenically unsaturated compound having at least one oxazoline group, a monoethylenically unsaturated compound having at least one carboxylic acid amide group and an ethylenically unsaturated compound are copolymerized with the final product from the first polymerization stage.

Abstract: A method for preparing ammonium tetrakis(pentafluorophenyl)borate salt comprising reacting a secondary amine with an aldehyde to form an iminium ion; hydrogenating the iminium ion by reaction with a reducing agent to form a tertiary amine; reacting the tertiary amine with a mineral acid to form an amine salt; and reacting the amine salt with K[B(C6F5)4], Li[B(C6F5)4], or combinations thereof to form an ammonium tetrakis(pentafluorophenyl)borate salt, wherein the secondary amine is derived from a non-animal source and the aldehyde has seven or more carbon atoms; wherein the ammonium tetrakis(pentafluorophenyl)borate salt is characterized by a solubility at 25° C. in hexane, cyclohexane or methylcyclohexane of at least 10 weight percent; and wherein the tertiary amine has a molecular weight of at least 450 g/mole is provided.

Abstract: The present invention relates to a process for preparing a solid catalyst component suitable for producing polyethylene and its copolymers, said process comprising the steps of: (a) contacting a dehydrated support having hydroxyl groups with a magnesium compound having the general formula MgR1R2; (b) contacting the product obtained in step (a) with modifying compounds (A) and/or (B) and/or (C), wherein: (A) is at least one oxygen and/or nitrogen comprising organic compound; (B) is a compound having the general formula R11f(R12O)gSiXh, (C) is a compound having the general formula (R13O)4M, and (c) contacting the product obtained in step (b) with a titanium halide compound having the general formula TiX4, wherein Ti is a titanium atom and X is a halide atom, wherein an organometallic compound is added either before step (a) and/or after step (c). The invention also relates to a solid catalyst component obtainable by said process.

Abstract: Embodiments of the present disclosure are directed towards metal complexes that can be utilized to form polymers. As an example, the present disclosure provides a metal complex of Formula (I) wherein M is Zr, Hf, or Ti; each Het is independently a heterocyclic; each L is independently a bridging group; each X is independently Cl, Br, I, or alkyl; each R1 is independently selected from the group including hydrogen, alkyls, alkenyls, alkynyls, cycloalkyls, aryls, acyls, aroyls, alkoxys, aryloxys, alkylthiols, dialkylamines, alkylamidos, alkoxycarbonyls, aryloxycarbonyls, carbomoyls, alkyl- and dialkyl-carbamoyls, acyloxys, acylaminos, aroylaminos, aromatic rings, fused aromatic rings, and combinations thereof; and each n is independently an integer having a value of one to five.

Abstract: The present invention relates to novel polymer compositions, to a process for their manufacturing, to the use of said polymer compositions for modifying the viscosity of aqueous compositions, and to water-borne coating compositions containing the novel polymer compositions as thickeners. The polymer compositions comprise a polymer material which is obtainable by reacting: a) a polymer P1 having at least one functional group of the formula (I), where k is an integer from 0 to 4; n is 0 or 1 p is an integer from 1 to 10, the number average of p being from 1.5 to 10; Q is a divalent moiety selected from the group consisting of —O— and —NH—; P is a p-valent hydrophilic neutral polymer radical; and R1 is as defined in the claims; with b) a succinic anhydride of the formula (II) where R is C4-C24-alkyl or C4-C24-alkenyl.

Abstract: The present invention relates to a method of preparing a modified conjugated diene-based polymer, and more particularly, to a method of preparing a modified conjugated diene-based polymer, including: (S1) preparing an active polymer with an organic metal bonded thereto by polymerizing a conjugated diene-based monomer in a hydrocarbon solvent in the presence of an organometallic compound; and (S2) mixing the active polymer prepared according to process S1 with a modifier, wherein the mixing of process S2 is performed at a Reynolds number of 20 or less for 1 minute or more, the Reynolds number being maintained within a range of ±5 of a Reynolds number when the modifier is added (wherein the range is between greater than 0 to 20 or less).

Abstract: Provided is a solid polymethylaluminoxane composition which has higher activity when being used as a co-catalyst in olefin polymerization. The solid polymethylaluminoxane composition contains polymethylaluminoxane, trimethylaluminum, and Al2O3, wherein: (i) the aluminum content is in a range of 36-43 mass %; and (ii) the Al2O3 content is in a range of 0.001-10 mol % represented in terms of aluminum.

Abstract: The present invention relates to a process for determining a set of one or more operating conditions of an olefin polymerization reactor for the synthesis of a polyolefin in slurry condition, comprising the steps of: a1) introducing a polyolefin into a volume of at least one diluent, said diluent being agitated by a powered agitator at a first temperature T1; b1) monitoring the power consumed by the agitator as a function of the concentration, for at least three concentrations C1, C2, and Cn, which are different from each other; c1) repeating steps a1) and b1) at two or more subsequent temperatures T2 and Tn, which are different from each other and from T1; d1) determining from the power consumed by the agitator as a function of concentration, said set of one or more stable operating conditions for the synthesis of the polyolefin in the olefin polymerization reactor.

Abstract: A process for preparing a procatalyst for polymerization of olefins, comprising contacting a magnesium-containing support with a halogen-containing titanium compound, a first internal electron donor represented by Formula A, a second internal electron donor represented by Formula B, and an activator; wherein the molar ratio of the first internal donor to the second internal donor is between 0.01 and 0.7; wherein in Formula A each R80 group is independently a substituted or unsubstituted aromatic group; and R81, R82, R83, R84, R85, R86 and R87 are each independently selected from a hydrogen or a hydrocarbyl group; wherein in Formula B R51 and R52 are each independently selected from a hydrogen or a hydrocarbyl group; and R53 and R54 are each independently selected from hydrogen, a halide or a hydrocarbyl group.

Abstract: Disclosed are saturated cyclic monopolymers derived from hexyne, octyne, nonyne, pentadecyne and saturated cyclic copolymers derived from acetylene and a second alkyne monomer that is hexyne, octyne, nonyne, or pentadecyne.

Abstract: Ethylene-based polymers comprising the following properties: (A) a density less than 0.9190 g/cc; (B) a hexane extractable level that meets the following equation: hexane extractable level ?A+B [log(12)], where A=2.65 wt %, and B—0.25 wt %[log (dg/min)]; based on total weight of the ethylene-based polymer; (C) a G? (at G?=500 Pa, 1 70° C.) that meets the following equation: G??C+D [log(12)], where C=150 Pa, and D=?60 Pa/[log(dg/min)]; and (D) a melt index (12) from 0.7 to 20 dg/min; are made in high pressure tubular process that comprises at least three reaction zones with the peak polymerization temperature of the first reaction zone ?320° C. and the peak polymerization temperature of the last reaction zone ?290° C.

Abstract: A gas-phase process for the homopolymerization or copolymerization of propylene with other olefins, including carrying out the polymerization in the presence of a catalyst system made from or containing: (a) a solid catalyst component made from or containing Mg, Ti, halogen, an electron donor selected from 1.3-diethers and an olefin polymer in a specific amount; (b) an aluminum alkyl compound and (c) an external electron donor (ED) compound, wherein components (b) and (c) being employed in amounts such that the Al/(ED) molar ratio ranges from about 2 to about 200.

Abstract: The present invention relates to a thermoplastic block copolymer comprising at least one PA block and at least one PB block. The PA block represents a polymer block comprising one or more units of monomer A, and the PB block represents a polymer block comprising one or more units of monomer B. Monomer A is a vinyl, acrylic, diolefin, nitrile, dinitrile, acrylonitrile monomer, a monomer with reactive functionality, or a crosslinking monomer. Monomer B is a radically polymerizable triglyceride or mixtures thereof, typically in the form of a plant or animal oil. The present invention also relates to a method of preparing a thermoplastic block copolymer or novel thermoplastic statistical copolymers by polymerizing a radically polymerizable monomer with a radically polymerizable triglyceride or mixtures thereof via reversible addition-fragmentation chain-transfer polymerization (RAFT), in the presence of an free radical initiator and a chain transfer agent.

Abstract: A polymeric compound is disclosed herein, having the general formula I: wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

Abstract: A process to form an ethylene-based polymer comprises polymerizing a reaction mixture comprising ethylene, at least one symmetrical polyene and at least one chain transfer agent system comprising at least one chain transfer agent (CTA) in the presence of at least one free-radical initiator and in a reactor configuration comprising at least two reaction zones, reaction zone 1 and reaction zone i (i?2), wherein reaction zone i is downstream from reaction zone 1. The ratio of “the activity of the CTA system of the feed to the first reaction zone” to the “activity of the CTA system of the cumulative feed to the reaction zone i,” (Z1/Zi), is less than or equal to (0.8?0.2*log(Cs)), wherein Cs is from 0.0001 to 10.

Abstract: A polymer obtained by a solution polymerization process comprising within a range from 0.5 to 20 wt % of cyclic olefin derived units, within a range from 0 wt % to 15 wt % C4 to C12 ?-olefin derived units, the remainder being ethylene derived units; and having a Mw/Mn of less than 2.5; a weight average molecular weight (Mw) within a range from 80,000 to 300,000 g/mole; and a g? value of greater than 0.95. The polymer may be formed in a solution polymerization process comprising combining in a solution cyclic olefins, ethylene, hydrogen and optionally C4 to C12 ?-olefins with a single-site catalyst to form the polymer, wherein the single-site catalyst is most preferably selected from unsymmetrical Group 4 bis-bridged cyclopentadienyl metallocenes.

Abstract: The invention relates to a fluorinated copolymers which are particularly based on vinylidene fluoride (VDF) or trifluoroethylene (TrFE) and particularly functionalized by functional and/or functionizable vinyl ethers. The invention also relates to methods for producing said copolymers, and to the applications thereof.

Abstract: A copolymer having tetrafluoroethylene units, hexafluoropropylene units, and units independently represented by formula in a range from 0.02 to 2 mole percent, based on the total amount of the copolymer. Rf is a linear or branched perfluoroalkyl group having from 1 to 8 carbon atoms and optionally interrupted by one or more —O— groups, z is 1 or 2, each n is independently from 1 to 6, and m is 0 or 1. The copolymer has a melt flow index in a range from 25 grams per 10 minutes to 35 grams per 10 minutes and has a combined number of unstable end groups and —CF2H end groups in a range from 25 per 106 carbon atoms up to 120 per 106 carbon atoms. The copolymer can be extruded to make articles, such as insulated cables. A method of making the copolymer is also disclosed.